Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

Biocon share price jumped over 4% to a fresh 52-week high on Thursday after reports stated that the company was evaluating an internal merger of its biosimilars arm, Biocon Biologics, with the parent ...

The board of Biocon has approved the issue of 11.26 crore equity shares of face value of ₹5 each to eligible institutions. Biocon has raised a sum of ₹4,150 crore through the QIP.

HYDERABAD, Jan 30 (Reuters) - Indian biopharma company Biocon (BION.NS), opens new tab reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which ...

Biocon announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 ...

NEW DELHI: Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion. The move is aimed at creating a unified biopharma powerhouse, ...

The firm's revenue from biosimilars grew 25% in the latest quarter. India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical ...

BENGALURU, Dec 6 (Reuters) - Indian biopharmaceutical company Biocon said on Saturday it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s ...

Of the total proceeds via the share sale, up to Rs 3,620 crore will be utilised mainly towards payment to Mylan Inc. (Viatris).

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...